https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Zongertinib Approved by FDA for Patients With Nonsquamous NSCLC With HER2 TKD Mutations

Zongertinib Approved by FDA for Patients With Nonsquamous NSCLC With HER2 TKD Mutations

The action is supported by positive safety and efficacy findings from the phase 1a/1b first-in-human Beamion LUNG-1 trial.

administrator

Related Articles